Onconic Therapeutics allocates Jaqbo sales revenue toward advancing its cancer and obesity treatment pipeline. Jaqbo’s second-half sales hit **60.2 billion won**, a **73% year-over-year increase**, with an operating profit margin of **23.1%** (13.9 billion won). The company leverages these gains to fund new drug development in oncology and metabolic disorders.
Onconic Therapeutics initiates a Phase 3 clinical trial for its **Zastaprazan injection** in China. The company also reaches a **$1 million milestone payment** from its Chinese licensing partner, **Livzon Pharmaceutical Group**. This trial marks a key step in advancing the drug candidate’s development under their collaboration.
Onconic Therapeutics secures marketing approval in India for its gastroesophageal reflux disease drug **Ja Q Bo (zastaprazan)**. The subsidiary of Jeil Pharmaceutical accelerates plans to expand commercialization globally following the regulatory nod. The drug represents a new treatment option in the digestive health market.
Onconic Therapeutics, a subsidiary of JEIL PHARMACEUTICAL, reports that its anticancer drug candidate **Nesuparib (JPI-547)** demonstrates potential to overcome resistance to existing PARP-inhibitor treatments. Research findings, published in the *British Journal of Cancer*, validate the drug’s efficacy in addressing a key limitation of current cancer therapies. The study highlights Nesuparib’s mechanism as a next-generation solution for patients with treatment-resistant tumors.
